Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets

Keyphrases

• Human Epidermal Growth Factor Receptor 2 (HER2) 100%
• Antibody Targeting 100%
• Ionizing Radiation 100%
• Therapeutic Monoclonal Antibody 100%
• Tumor Cells 50%
• Trastuzumab 50%
• Antibody-dependent Cellular Cytotoxicity 50%
• Tumor 25%
• Response Rate 25%
• Breast Cancer Cell Lines 25%
• Therapeutic Target 25%
• Hematological Malignancies 25%
• Monotherapy 25%
• Total Protein 25%
• Protein Expression 25%
• Targeted Therapy 25%
• Monoclonal Antibody 25%
• Stem Cell Population 25%
• Cell Surface 25%
• Cytotoxic T Cells 25%
• Molecular Targets 25%
• Intracellular Reactive Oxygen Species 25%
• Radiation Exposure 25%
• Patient Demographics 25%
• Functional Significance 25%
• Phenotypic Change 25%
• Radiation Effects 25%
• Cell Interaction 25%
• Cell Toxicity 25%
• Solid Malignancies 25%
• Immunomodulation 25%
• Poor Response 25%
• CD20 25%
• Triple Negative 25%
• Cell Surface Proteins 25%
• Antiproliferative Effect 25%
• HER2 Targeting 25%

Medicine and Dentistry

• Ionizing Radiation 100%
• Monoclonal Antibody Therapy 100%
• Antibody Therapy of Cancer 100%
• Upregulation 75%
• Tumor Cell 50%
• Single Drug Dose 50%
• Antibody Dependent Cellular Cytotoxicity 50%
• Trastuzumab 50%
• Monotherapy 25%
• Hematologic Malignancy 25%
• Cell Population 25%
• Targeted Therapy 25%
• Immunotherapy 25%
• Cell Surface 25%
• Protein Expression 25%
• Tumor 25%
• Cytotoxic T-Cell 25%
• Radiation Exposure 25%
• Monoclonal Antibody 25%
• Epidermal Growth Factor Receptor 25%
• Patient Population 25%
• CD20 25%
• Cell Interaction 25%
• Sensitization 25%
• Breast Cancer Cell Line 25%
• Stem Cell 25%
• Cell Surface Protein 25%
• Antiproliferative Activity 25%
• Reactive Oxygen Species 25%

Immunology and Microbiology

• Monoclonal Antibody Therapy 100%
• Upregulation 75%
• Tumor Cell 50%
• Cell Surface 50%
• Trastuzumab 50%
• Antibody-Dependent Cell-Mediated Cytotoxicity 50%
• Cell Population 25%
• Stem Cell 25%
• Monoclonal Antibody 25%
• Cytotoxic T Cell 25%
• Protein Expression 25%
• Immunotherapy 25%
• CD20 25%
• Cell Interaction 25%
• Sensitization 25%
• Breast Cancer Cell Line 25%
• Antiproliferative Activity 25%
• Dioxygen 25%